Gordon R. Bernard is Director at CUMBERLAND PHARMACEUTICALS INC (CPIX). They have made 13 open-market trades across 1 company since 2011, most recently 2019-12-04.
CIK 0001470015
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CPIX | 1,000 | $7K |
Shares reported on the most recent Form 4, priced at the 2019-09-27 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CPIX | SELL · 10b5-1 | 2019-12-04 | 2019-12-06 | $4.79 | $5K | +1.6% | +0.2% | -20.3% |
| CPIX | SELL | 2019-09-20 | 2019-09-27 | $5.29 | $61K | -2.8% | -4.6% | -10.8% |
| CPIX | SELL | 2019-09-13 | 2019-09-20 | $5.09 | $56K | +3.2% | +2.0% | -1.7% |
| CPIX | SELL | 2019-09-06 | 2019-09-13 | $5.16 | $49K | +4.6% | +12.4% | +3.1% |
| CPIX | SELL | 2019-08-23 | 2019-08-30 | $5.16 | $16K | +7.1% | +23.5% | -0.2% |
| CPIX | SELL | 2019-08-15 | 2019-08-23 | $5.46 | $34K | -7.0% | +2.8% | -9.7% |
| CPIX | SELL | 2019-08-01 | 2019-08-16 | $5.92 | $37K | -11.7% | -9.2% | -8.6% |
| CPIX | SELL | 2019-07-18 | 2019-08-02 | $5.82 | $28K | -8.3% | -21.2% | -13.1% |
| CPIX | SELL | 2019-07-11 | 2019-07-19 | $5.77 | $43K | +4.7% | -3.2% | -5.7% |
| CPIX | SELL | 2019-06-27 | 2019-07-12 | $6.28 | $90K | +3.4% | +3.4% | -0.5% |
| CPIX | SELL | 2019-06-20 | 2019-06-28 | $6.31 | $84K | -8.3% | -11.1% | -10.3% |
| CPIX | SELL | 2019-06-13 | 2019-06-21 | $6.22 | $55K | -0.5% | -11.3% | -17.1% |
| CPIX | SELL | 2019-05-28 | 2019-06-14 | $6.28 | $136K | +1.1% | -8.4% | -18.2% |
| CPIX | SELL | 2011-11-21 | 2011-11-22 | $5.73 | $8K | -4.8% | -2.1% | -2.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.